Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cephalon
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented indolent or transformed B-Cell NHL indolent NHL: follicular B-Cell lymphoma, diffuse small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma
Documented refractory disease to rituximab therapy, given as a single agent or in combination (defined as no response, or progression within 6 months of completing rituximab treatment.)
Age of at least 18 years at Screening Visit (Site specific requirement may differ)
You may not be if
Previous chemotherapy or immunotherapy within 3 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin) or failure to recover from adverse events due to any agents administered previously.
Use of investigational agents within 28 days of study
History of prior high dose chemotherapy with allogeneic stem cell support
